Drug intelligence / Profile preview

mang-ji-shi

Development stage: Unknown
Lead developer: Beijing Hospital of Traditional Chinese Medicine
Modality: Small Molecules
Administration: Oral

Overview

Mang-Ji-Shi is a traditional Chinese medicine (TCM) formulation currently under investigation as a capsule for the treatment of primary hyperlipidemia. It is being evaluated in phase 2 clinical trials for its efficacy and safety in lowering lipid levels. The precise herbal composition and mechanism of action are not detailed in available sources, but as a TCM product, it likely contains multiple plant-derived ingredients aimed at regulating lipid metabolism and improving blood lipid profiles[1][3]. The drug is administered orally.

Brand names: Mang-Ji-Shi capsule
Other names: mang-ji-shiMang-Ji-Shi capsule

Beyond the preview

Go deeper on mang-ji-shi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mang-ji-shi.

Explore the full profile